durvalumab + etoposide + carboplatin or cisplatin + thoracic radiotherapy

This investigational combination treatment regimen is being evaluated in the Phase 2 CHEST-RT trial (TROG 20.01) for the first-line treatment of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The regimen consists of a standard-of-care chemo-immunotherapy backbone—comprising the PD-L1 inhibitor durvalumab and platinum-based chemotherapy (etoposide combined with either carboplatin or cisplatin)—supplemented by the addition of concurrent or consolidation thoracic radiotherapy (TRT). Durvalumab is a human monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with PD-1 and CD80, thereby restoring anti-tumor T-cell activity. The chemotherapy components induce cytotoxic effects through DNA damage and topoisomerase II inhibition, while the addition of radiotherapy aims to improve local control and potentially enhance systemic immune responses. The study is sponsored by the Trans Tasman Radiation Oncology Group to assess the safety and feasibility of this integrated approach.

Brand names

ImfinziEtopophosParaplatinPlatinol

Other names

etoposide + carboplatin or cisplatin-Trans Tasman Radiation Oncology Group-small-cell lung cancer (extensive-stage)Durvalumab + Chemo + RT in ES-SCLC